One of these brakes is the Programmed cell death protein 1 (PD-1), where blocking this receptor and its ligand, PD-L1 with monoclonal antibodies (MABs) has revolutionized cancer treatment over the last few years [2]. This evidence concerns the gene PDCD1 and cancer.